CEMEX, S.A.B. de C.V. (NYSE:CX) released that it has closed the series of transactions with Holcim, originally released on August 28, 2013 as well as supplemented on October 30, 2014. CEMEX purchased all of Holcim’s assets in the Czech Republic and divested its assets in the western division of Germany to Holcim. On Friday shares of CEMEX, S.A.B. de C.V. (NYSE:CX) closed at $10.23. Company’s sales growth for last 5 years was -2.80% and EPS growth for next 5 years is recorded as 2.40%.
Leading microcontroller and touch technology solutions provider, Atmel Corporation (NASDAQ:ATML ), recently commenced the sampling procedure of its next generation maXStylus mXTS220 to various global customers. Atmel Corporation (NASDAQ:ATML) in last trading activity moved up 1.32% to close at $8.46. Company weekly performance is 0.83% while its quarterly performance stands at 13.25%. Atmel Corporation (NASDAQ:ATML) is -13.32% away from its 52 week high.
Bristol-Myers Squibb Co (NYSE:BMY) announced that the Phase-III trial of its experimental lung-cancer treatment Opdivo has been terminated earlier-than-anticipated. The termination came after an independent monitoring committee concluded that the said drug had superior efficacy results, as compared to docetaxel, a chemotherapy drug used for treating lung cancer patients. Bristol-Myers Squibb Company (NYSE:BMY) in last trading activity fell -0.66% to close at $60.32. Company weekly performance is 1.36% while its quarterly performance stands at 22.63%. Bristol-Myers Squibb Company (NYSE:BMY) is -1.73% away from its 52 week high.
Stock analysts at Stifel Nicolaus initiated coverage on shares of Zulily (NASDAQ:ZU) in a report issued on Friday. The firm set a “buy” rating on the stock. On last trading day zulily, Inc. (NASDAQ:ZU) advanced 0.72% to close at $22.27. Its volatility for the week is 6.43% while volatility for the month is 4.99%. ZU’s EPS growth for past 5 years was 0.00%. zulily, Inc. (NASDAQ:ZU) monthly performance is -15.87%.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, on 7 January 2015 announced that David P. Luci, President & Chief Executive Officer, will be presenting at the Biotech Showcase™ 2015 Conference being held in San Francisco, California. On last trading day Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) fell -3.35% to close at $13.00. Its volatility for the week is 9.23% while volatility for the month is 5.66%. DPRX’s EPS growth for past 5 years was 0.00%. Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) monthly performance is 22.18%.